Business Description
Karyopharm Therapeutics Inc
NAICS : 325412
SIC : 5999
ISIN : US48576U1060
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.08 | |||||
Equity-to-Asset | -0.57 | |||||
Debt-to-Equity | -1.3 | |||||
Debt-to-EBITDA | -1.5 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -8.67 | |||||
Beneish M-Score | -2.9 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -5.2 | |||||
3-Year EBITDA Growth Rate | 23.7 | |||||
3-Year EPS without NRI Growth Rate | 22.8 | |||||
3-Year FCF Growth Rate | 28.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 16.56 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 25.43 | |||||
9-Day RSI | 33.39 | |||||
14-Day RSI | 38.34 | |||||
6-1 Month Momentum % | 64.32 | |||||
12-1 Month Momentum % | -63.21 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.37 | |||||
Quick Ratio | 3.32 | |||||
Cash Ratio | 2.76 | |||||
Days Inventory | 263.98 | |||||
Days Sales Outstanding | 89.71 | |||||
Days Payable | 268.41 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.8 | |||||
Shareholder Yield % | 1.51 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 96.62 | |||||
Operating Margin % | -88.71 | |||||
Net Margin % | -97.99 | |||||
FCF Margin % | -63.53 | |||||
ROA % | -47.95 | |||||
ROIC % | -631.41 | |||||
ROC (Joel Greenblatt) % | -1502.43 | |||||
ROCE % | -50.65 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.83 | |||||
EV-to-EBIT | -0.92 | |||||
EV-to-EBITDA | -0.92 | |||||
EV-to-Revenue | 0.75 | |||||
EV-to-Forward-Revenue | 0.75 | |||||
EV-to-FCF | -1.18 | |||||
Price-to-Median-PS-Value | 0.02 | |||||
Earnings Yield (Greenblatt) % | -108.99 | |||||
FCF Yield % | -75.31 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Karyopharm Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 135.515 | ||
EPS (TTM) (€) | -1.159 | ||
Beta | -0.2 | ||
Volatility % | 87.68 | ||
14-Day RSI | 38.34 | ||
14-Day ATR (€) | 0.070485 | ||
20-Day SMA (€) | 1.1572 | ||
12-1 Month Momentum % | -63.21 | ||
52-Week Range (€) | 0.5866 - 3.421 | ||
Shares Outstanding (Mil) | 116.47 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Karyopharm Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Karyopharm Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Karyopharm Therapeutics Inc Frequently Asked Questions
What is Karyopharm Therapeutics Inc(STU:25K)'s stock price today?
When is next earnings date of Karyopharm Therapeutics Inc(STU:25K)?
Does Karyopharm Therapeutics Inc(STU:25K) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |